PERJETA is indicated for use in combination with Herceptin® (trastuzumab) and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) at high risk of recurrence.1

Discover how the APHINITY trial evaluated PERJETA + Herceptin-based adjuvant therapy in patients with HER2+ EBC.

Learn about the APHINITY trial design, endpoints, and baseline characteristics

See data from the APHINITY adjuvant trial

Review the adverse reactions in adjuvant trials

Understand the appropriate dosing schedule and duration of treatment

Patients with HER2+ EBC eligible to receive up to 1 year (18 cycles) of PERJETA + Herceptin-based therapy:

Patients who begin PERJETA and Herceptin in the neoadjuvant setting should continue to receive PERJETA and Herceptin, every 3 weeks, to complete 1 year (up to 18 cycles) or until disease recurrence or unmanageable toxicity, whichever occurs first.1

Patients who begin treatment in the adjuvant setting should receive a total of 1 year (up to 18 cycles) of PERJETA and Herceptin-based therapy, every 3 weeks, starting on Day 1 of the first taxane-containing cycle.

Patients should discontinue treatment before 1 year if they experience disease recurrence or unmanageable side effects.

Reference